Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Net Income towards Common Stockholders: 2023-2024

Historic Net Income towards Common Stockholders for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$161.3 million.

  • Zenas BioPharma's Net Income towards Common Stockholders fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 50.07%. This contributed to the annual value of -$161.3 million for FY2024, which is 334.62% down from last year.
  • According to the latest figures from FY2024, Zenas BioPharma's Net Income towards Common Stockholders is -$161.3 million, which was down 334.62% from -$37.1 million recorded in FY2023.
  • Over the past 5 years, Zenas BioPharma's Net Income towards Common Stockholders peaked at -$37.1 million during FY2023, and registered a low of -$161.3 million during FY2024.
  • Over the past 2 years, Zenas BioPharma's median Net Income towards Common Stockholders value was -$99.2 million (recorded in 2023), while the average stood at -$99.2 million.
  • Data for Zenas BioPharma's Net Income towards Common Stockholders shows a maximum YoY tumbled of 334.62% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Net Income towards Common Stockholders (Yearly) stood at -$37.1 million in 2023, then tumbled by 334.62% to -$161.3 million in 2024.